Roivant's lung disease drug fails mid-stage trial-March 2024-www.financetom.com

Roivant's lung disease drug fails mid-stage trial

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Roivant's lung disease drug fails mid-stage trial

Dec 3, 2024 4:35 AM

Dec 3 (Reuters) - Roivant said on Tuesday its

drug did not meet the main goal in a mid-stage trial evaluating

it in patients with a type of lung disease.

(Reporting by Christy Santhosh in Bengaluru; Editing by

Shinjini Ganguli)

Previous page： Judge declares Venezuelan bonds valid, creditors press for Citgo auction resolution Next page： Santos always prepared to consider any takeover offers, CEO says

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Judge declares Venezuelan bonds valid, creditors press for Citgo auction resolution

Sep 20, 2025

* Judge Failla rules PDVSA's 2020 bonds valid under Venezuelan law * Citgo's assets at risk due to PDVSA's default * Delaware Judge Stark moves to support Amber Energy's bid for Citgo parent (Recasts lede, adds decisions by Delaware judge in paragraphs 11-14) By Luc Cohen and Marianna Parraga NEW YORK/HOUSTON, Sept 18 (Reuters) - A U.S. judge upheld the...

Santos always prepared to consider any takeover offers, CEO says

Sep 20, 2025

SYDNEY (Reuters) -Santos is always prepared to consider any takeover offers for the company, the Australian gas producer's CEO Kevin Gallagher said on Friday, adding he would like to stay as CEO as long as he has the support of shareholders and the board. An $18.7 billion bid for Santos by a consortium led by Abu Dhabi National Oil Company...

China's DeepSeek says its hit AI model cost just $294,000 to train

Sep 20, 2025

* DeepSeek's R1 model attracted global attention in January * Article in Nature reveals R1's compute training costs for the first time * DeepSeek also addresses claims it distilled OpenAI's models in peer-reviewed article (This Sept 18 story was updated on Sept 19 to add context on distillation in paragraphs 14-20) By Eduardo Baptista BEIJING, Sept 18 (Reuters) - Chinese...

China's DeepSeek says its hit AI model cost just $294,000 to train

Sep 20, 2025

BEIJING (Reuters) - Chinese AI developer DeepSeek said it spent $294,000 on training its R1 model, much lower than figures reported for U.S. rivals, in a paper that is likely to reignite debate over Beijing's place in the race to develop artificial intelligence. The rare update from the Hangzhou-based company - the first estimate it has released of R1's training...